Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas, Inc. submitted a Form 144 notifying the proposed sale of 3,609 shares of common stock in connection with the settlement of vested restricted stock units on 02/23/2026. The filing also reports a prior sale of 4,592 shares on 02/13/2026. The broker listed is Morgan Stanley Smith Barney LLC.
Arvinas, Inc. filed a notice for the proposed sale of 4,786 common shares through Morgan Stanley Smith Barney LLC, reflecting the settlement of vested restricted stock units on 02/23/2026.
The filing also reports an earlier sale by Randy Teel of 4,403 common shares on 02/13/2026 for $52,359.96.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 4,403 shares of common stock on February 13, 2026 at $11.89 per share. According to the filing, the issuer executed this sale solely to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2026, and it was not a discretionary trade. Following this transaction, Teel beneficially owned 154,482 shares of Arvinas common stock directly.
Arvinas, Inc.’s Chief Financial Officer Andrew Saik reported an automatic share sale related to tax withholding. On February 13, 2026, 5,134 shares of common stock were sold at $11.89 per share to cover tax obligations triggered by the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The filing notes this was not a discretionary trade. After this transaction, Saik’s directly held stake is 159,267 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding. On February 13, 2026, 4,592 shares of common stock were sold in an open-market transaction at $11.89 per share to cover tax obligations from RSU vesting. After this transaction, Cacace directly owned 151,232 common shares, which include 1,576 shares previously acquired under the company’s 2018 Employee Stock Purchase Plan. The filing notes the sale did not represent a discretionary trade.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic sale of 5,685 shares of common stock at $11.89 per share. The shares were sold by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The transaction was not a discretionary trade. After this sale, Berkowitz directly holds 163,938 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock to cover taxes tied to restricted stock units. On February 13, he sold 1,016 shares of common stock at an average price of $11.89 per share in an open-market transaction.
The footnotes explain this sale was made by the company to satisfy tax withholding obligations upon vesting and settlement of 25% of RSUs granted on February 13, 2025, and that it was not a discretionary trade. After this sale, Loomis directly owns 30,800 shares, including 119 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas, Inc. President and CEO Randy Teel reports his direct holdings of common stock and stock options in the company. The filing lists multiple option and restricted stock unit grants made between 2018 and 2025, with vesting schedules extending through 2029 and generally contingent on continued service. It also notes shares previously purchased under the 2018 Employee Stock Purchase Plan. The report does not show any stock purchases or sales, only existing equity awards and holdings.
Arvinas, Inc. shareholder plans a modest Rule 144 stock sale. A holder has filed to sell 5,685 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or around 02/13/2026 on the NASDAQ.
The filing lists an aggregate market value of 67,605.35 for the shares to be sold, compared with 64,224,294 Arvinas common shares outstanding. The shares were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc.
A shareholder of Arvinas, Inc. has filed a notice to sell 4,592 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 54607.52. The issuer had 64224294 shares outstanding, and the approximate sale date is 02/13/2026.
The securities were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc., with payment also dated 02/13/2026 and described as not applicable, indicating no separate cash purchase at that time.